




מדינת ישראל
STATE OF ISRAEL

Best Available Copy

10/530963
CT/L 03/00815
Rec'd PCT/PTO 11 APR 2003 #2



Ministry of Justice
Patent Office

משרד המשפטים
לשכת הפטנטים

This is to certify that
annexed hereto is a true
copy of the documents as
originally deposited with
the patent application
of which particulars are
specified on the first page
of the annex.

זאת לתעודה כי
רצופים בזה העתקים
נכונים של המסמכים
שהופקדו לכתחילה
עם הבקשה לפטנט
לפי הפרטים הרשומים
בעמוד הראשון של
הנספח.

PRIORITY DOCUMENT

SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)



This 21-10-2003 היום
על הבהונים
רשם הפטנטים
Commissioner of Patents

נתאשר
Certified

מספר : 152232 Number
תאריך : 10.10.2002 Date
הוקדם/נדחה Post-dated 10-10-2002

Application for Patent

אני, (שם, המבקש, מענו ולגבי גוף מאוגד - מקום התאגדותו)
I (Name and address of applicant, and in case of body corporate - place of incorporation)

ממציאים :

Hurgin Vladimir
Novick Daniela
Rubinstein Menachem

Yeda Research and Development Co. Ltd
An Israeli Company
At Weizmann Institute of Science
P.O.Box 95
Rehovot 76100, Israel

ידע חברה למחקר ולפיתוח בע"מ
חברה ישראלית
ליד מכון ויצמן למדע
ת.ד. 95
רחובות 76100

wner, : Assignment

העברה

בעל אמצאה מכח
by virtue of

vention the title of which is
(Hebrew)

ששמה הוא פרומוטר ל IL-18BP, הכנתו והשימוש בו
(בעברית)

omoter to IL-18BP, its preparation and use

(באנגלית)

English)

reby apply for a patent to be granted to me in respect thereof.

מבקש בזאת כי יינתן עליה פטנט

• בקשת חלוקה - Application of Division	• בקשת פטנט מוסף - Application for Patent Addition	דרישת דין קדימה Priority Claim		
מבקשת פטנט from Application	• לבקשה/לפטנט to Patent/Apl.	מספר/סימן Number/Mark	תאריך Date	מדינת האגוד Convention Country
No. Dated	No. Dated			
• ייפוי כוח : כלל/ מיוחד - רצוף/ בזה/ עוד יוגש I.O.A.: general/ individual - attached/to be filed later הוגש בעניין filed in case				
המען למסירת מסמכים בישראל: Address for Service in Israel הנרי עינב - עורך פטנטים. אינטר-לאב בע"מ קרית ויצמן נס ציונה 76100				

or the Applicant:
חתימת המבקש
Signature of Applicant
נרי עינב - עורך פטנטים
nry Einav - Patent Attorney

היום 10 בחודש אוקטובר שנת 2002
This 10 of the year October of 2002

לשימוש הלשכה
For Office Use

טופס זה, כשהוא מוטבע בחותם לשכת הפטנטים ומושלם במספר ובתאריך ההגשה, הינו אישור להגשת הבקשה שפרטיה רשומים לעיל.
This form, impressed with the Seal of the Patent Office and indicating the number and date of filing, certifies the filing of the application particulars of which are set out above.

Delete whatever is inapplicable

• מחק את המיותר

פרומוטר ל IL-18BP , הכנתו והשימוש בו

**Promoter to IL-18BP,
its preparation and use**

Applicant: Yeda Research and Development Co. Ltd

Ref: 596

Inventors: Vladimir Hurgin, Novick Daniela, Rubinstein Menachem

5 FIELD OF THE INVENTION

The present invention relates to the promoter of interleukin-18 binding protein (IL-18BP), to its preparation and use.

BACKGROUND OF THE INVENTION

10

Cytokine binding proteins (soluble cytokine receptors) are usually the extracellular ligand binding domains of their respective cell surface cytokine receptors. They are produced either by alternative splicing or by proteolytic cleavage of the cell surface receptor. These soluble receptors have been described in the past: for example, the soluble
15 receptors for IL-6 and IFN γ (Novick et al. 1989), TNF (Engelmann et al. 1989 and Engelmann et al. 1990), IL-1 and IL-4 (Maliszewski et al. 1990) and IFN α/β (Novick et al. 1994, Novick et al. 1992). One cytokine-binding protein, named osteoprotegerin (OPG, also known as osteoclast inhibitory factor - OCIF), a member of the TNFR/Fas family, appears to be the first example of a soluble receptor that exists only as a secreted protein
20 (Anderson et al. 1997, Simonet et al. 1997, Yasuda et al. 1998).

An interleukin-18 binding protein (IL-18BP) was affinity purified, on an IL-18 column, from urine (Novick et al. 1999). IL-18BP abolishes IL-18 induction of IFN γ , and IL-18 activation of NF-kB *in vitro*. In addition, IL-18-BP inhibits induction of IFN γ in mice injected with LPS. The IL-18BP gene was localized to the human chromosome 11,
25 and no exon coding for a transmembrane domain could be found in the 8.3 kb genomic sequence comprising the IL-18BP gene. Four isoforms of IL-18BP generated by alternative mRNA splicing have been found in humans so far. They were designated IL-18BP a, b, c, and d, all sharing the same N-terminus and differing in the C-terminus (Novick et al 1999).

These isoforms vary in their ability to bind IL-18 (Kim et al. 2000). Of the four, human IL-18BP (hIL-18BP) isoforms a and c are known to have a neutralizing capacity for IL-18. The most abundant IL-18BP isoform, the spliced variant isoform a, exhibits a high affinity for IL-18 with a rapid on-rate and a slow off-rate, and a dissociation constant (Kd) of approximately 0.4 nM (Kim et al. 2000). IL-18BP is constitutively expressed in the spleen (Novick 1999), and circulates at plasma concentrations of 2.5 ng/ml (Novick et al. 2001). The residues involved in the interaction of IL-18 with IL-18BP have been described through the use of computer modelling (Kim et al. 2000) and based on the interaction between the similar protein IL-1 β with the IL-1R type I (Vigers et al. 1997). According to the model of IL-18 binding to the IL-18BP, the Glu residue at position 42 and Lys residue at position 89 of IL-18 have been proposed to bind to Lys-130 and Glu-114 in IL-18BP, respectively (Kim et al. 2000).

As mentioned, IL-18 induces IFN γ which, in turn, was recently reported to induce IL-18BP α mRNA generation *in vitro* (Muhl et al 2000). Therefore, IL-18BP α could serve as a “shut off” signal, terminating the inflammatory response.

IL-18BP is significantly homologous to a family of proteins encoded by several Poxviruses (Novick et al.1999, Xiang and Moss 1999). Inhibition of IL-18 by this putative viral IL-18BP may attenuate the inflammatory antiviral Th1 response.

Serum IL-18BP is significantly elevated in sepsis, indicating its role in regulating immune responses *in vivo* (Novick et al. 2001). Indeed, IL-18BP is induced by IFN γ in various cells, suggesting that it serves as a negative feedback inhibitor of the IL-18-mediated immune response (Mughl et al. 2000)

Preliminary results indicate that IL-18BP mRNA is detected in leukocytes, colon, small intestine, prostate and particularly in spleen cells (Novick et al.1999). The component cells of the spleen consist of macrophages, lymphocytes, and plasma cells with additional cells derived from the circulation.

The activity of elements that control transcription, promoter and enhancers vary considerably among different cell types. Promoters and enhancers consist of short arrays of DNA sequences that interact specifically with cellular proteins involved in transcription (reviewed in Dynan and Tjian 1985, McKnight and Tjian 1986, Sassone-Corsi and Borrelli 1986 and Maniatis et al 1987). The combination of different recognition sequences and the amounts of the cognate transcription factors determine efficiency with which a given gene is transcribed in a particular cell type. Many eukaryotic promoters contain two types of recognition sequences: the TATA box and the upstream promoter elements. The TATA box, located 25-30 bp upstream of the transcription initiation site, is thought to be involved in directing RNA polymerase II to begin RNA synthesis at the correct site. In contrast, the upstream promoter elements determine the rate at which transcription is initiated. Enhancer elements can stimulate transcription up to 1000-fold from linked homologous or heterologous promoters. However unlike upstream promoter elements, enhancers are active when placed downstream from the transcription initiation site or at considerable distance from the promoter. Many enhancers of cellular genes work exclusively in a particular tissue or cell type (reviewed by Voss et al. 1986, Maniatis et al. 1987). In addition some enhancers become active only under specific conditions that are generated by the presence of an inducer, such as a hormone or metal ion (reviewed by Sassone-Corsi and Borrelli 1986 and Maniatis 1987). Because of these differences in cell specificities of cellular enhancers, the choice of promoter and enhancer elements to be incorporated into a eukaryotic expression vector will be determined by the cell types in which the recombinant gene is to be expressed. Conversely, the use of a prefabricated vector containing a specific promoter and cellular enhancer may severely limit the cell types in which expression can be obtained.

Many enhancer elements derived from viruses have a broader host range and are active in a variety of tissues, although significant quantitative differences are observed among the different cell types. For example, the SV40 early enhancer is promiscuously active in many cell types derived from a variety of mammalian species, and vectors incorporating this enhancer have consequently been used (Dijkema et al. 1985). Two other enhancer/promoter combinations that are active in a broad range of cells are derived from

the long repeat (LTR) of the Rous sarcoma virus genome (Gorman et al 1982b) and from human cytomegalovirus (Boshart et al. 1985).

SUMMARY OF THE INVENTION

5 The present invention relates to a DNA sequence comprising SEQ ID NO:1 encoding the human IL-18BP promoter, or a fragment or a functional derivative thereof, such as those of SEQ ID NO:2 and SEQ ID NO:3. The invention relates also to the IL-18BP promoter operatively linked to the gene encoding IL-18BP or to a gene encoding a heterologous protein, such as luciferase, interferon-beta, TNF, erythropoietin, tissue plasminogen activator, granulocyte colony stimulating factor, manganese-superoxide dismutase, an
10 immunoglobulin, or fragment thereof, growth hormone, FSH, hCG, IL-18, hsLDLR and TNF receptor binding proteins.

In one aspect, the invention relates to a vector comprising the DNA of the invention, a host cell e.g. CHO, WISH, HepG2, Cos, CV-1, HeLA, and Hakat U937 cells, harbouring such a vector, and a method for the production of a recombinant protein comprising
15 culturing such host cell and isolating the recombinant protein produced.

In another aspect, the invention provides a recombinant virus vector which comprises a portion of the virus genome and a DNA fragment encoding a gene of interest and a DNA fragment comprising SEQ ID NO:1 or a fragment, or a functional derivative thereof encoding the human IL-18BP promoter, operably linked to the gene of interest. The
20 portion of the virus may belong e.g. to an adeno associated virus or to a retrovirus.

In addition the invention provides a method of regulating cell specific expression of a gene of interest, for the treatment of a disease, such as HIV infection or for the treatment of hematopoietic disorders, comprising stably transducing a target mammalian immune cell, e.g. an hematopoietic stem cell, with a vector virus according to the invention and
25 transplanting such cell in an individual in need.

The invention further relates to a method of gene therapy for the treatment of a disease in an individual exhibiting elevated IFN γ in a body tissue, comprising the administration of an effective amount of a virus vector according to the invention. More specifically the

method may further comprise administration of IL-6 and/or TNF- α and or IRF and or C/EBP β factors.

The invention provides transgenic mice harbouring the human IL-18BP promoter.

5

BRIEF DESCRIPTION OF THE FIGURES

- 10 **Figure 1** shows a schematic representation of the promoter region of the IL-18BP gene, including the 5 regulatory elements.

Figure 2 shows the Kinetics of IL-18BP induction and synergy with TNF α and IL-6. (A) IFN γ induces IL-18BP in a dose and time-dependent manner in human WISH cells. Cells
15 were incubated with the indicated concentrations of IFN γ for 24 and 48 h. (B) Synergistic effects of TNF α , IL-6 and their combination on IFN γ -induced IL-18BP. HepG2 cells were incubated with the indicated combinations of IFN γ (100 U/ml), TNF α (20 ng/ml) and IL-6 (300 U/ml). Induction of IL-18BP by each combination was significantly higher ($p < 0.05$) than induction by IFN γ alone. Data are mean \pm SD ($n=3$, for A. $n=4$, for B)

20

Figure 3. shows a schematic representation of the conserved exon-intron organization of the human and mouse IL-18BP genes. The human IL-18BP α gene was compared with the mouse IL-18BP δ gene. Exons are indicated. Transcription start site, translation start site (ATG), stop codon (Stop) and the polyadenylation signal (PAS) are indicated for the
25 human IL-18BP α gene.

Figure 4 shows that the induction of IL-18BP by IFN γ is at the transcriptional level and depends on *de novo* protein synthesis. (A) semi-quantitative RT-PCR of IL-18BP mRNA

from HepG2 cells that were pre-incubated with actinomycin D (1 μ g/ml, 30 min), washed and incubated with IFN γ (100 U/ml) for the indicated times. RT-PCR of β actin mRNA is shown as a control (B) semi-quantitative RT-PCR of IL-18BP mRNA from HepG2 cells that were pre-incubated with cycloheximide (20 μ g/ml) and IFN γ (100 U/ml) for the indicated times.

Fig. 5 shows the basal and IFN γ -induced activity of luciferase reporter vectors carrying the human IL-18BP promoter. Insert size, extending from the transcription start site (+1) is given in parentheses. Circled numbers represent the various response elements: 1. GAS. 2. IRF-E. 3. C/EBP-E (2 sites). Scilencer 5. Distal enhancer. Filled squares depict mutation in a specific response element. HepG2 cells were co-transfected with the indicated reporter vector and pSV40 β GAL. All luciferase values were normalized to β galactosidase activity. (A) luciferase activity in extracts of un-induced cells relative to that of cells transfected with pGL3 – Basic vector. (B) luciferase activity in cells transfected with selected vectors and induced with IFN γ . Fold induction is over basal activity as given in (A).

Figure 6 shows that IRF-1 is essential for IL-18BP expression in mice. Serum IL-18BP of C57Bl/6 IRF-1^{-/-} and control C57 Bl/6 mice that were injected intraperitoneally with murine IFN γ (53,000 u/mouse). Mice were bled before injection and 24 h post injection. Serum IL-18BP was determined by ELISA. Data are mean \pm SE (n=6 for each group). The differences between serum IL-18BP in control and IRF-deficient mice, as well as the induction of IL-18BP in control mice were statistically significant (p < 0.05).

Figure 7 shows the role of IRF-1 and C/EBP β in IL-18BP gene induction and their association. (A) electrophoretic mobility shift assay (EMSA Example 18) of dsDNA probes corresponding to bases -33 to -75 (IRF-E, left panel) and -8 to -55 (GAS, right panel). HepG2 cells were treated with IFN γ for the indicated times and nuclear extracts were allowed to react with the IRF-E or GAS probes. Shifted bands are indicated by filled arrowheads. The GAS complex was also subjected to super shift with the indicated

antibodies. The super shifted band is indicated by an open arrowhead. (B) semi-quantitative RT-PCR of IL-18BP mRNA from HepG2 cells that were transfected with the indicated combinations of IRF-1 or C/EBP β expression vectors. Where indicated, IFN γ was added and cells were harvested 5 h later. Values were normalized to β actin mRNA. (C) luciferase activity in cells transfected with the luciferase reporter vector pGL3(1272), containing the complete IL-18BP promoter, together with the indicated concentration of pCDNA3-IRF-1 (circles) and 1 μ g/10⁶ cells of pCDNA3-C/EBP β . Alternatively, cells were transfected with the indicated concentration of pCDNA3-C/EBP β (squares) and 0.1 μ g/10⁶ cells of pCDNA3-IRF-1. Luciferase activity was normalized by the β Gal activity. (D) immunoblots of nuclear and cytoplasmic extracts (see Example 17 for preparation of extracts) of cells treated with IFN γ (100 U/ml, 2 h). Extracts were immunoprecipitated (IP) and immunoblotted (IB) with the indicated antibodies.

Figure 8 shows the factors binding to the promoter of IL-18BP upon IFN γ induction (A) EMSA with the proximal C/EBP β E and whole cell extracts following treatment with IFN γ . Where indicated, the extracts were super shifted with the indicated antibodies. (B) EMSA with a probe corresponding to the distal enhancer and whole cell extracts following treatment with IFN γ . Where indicated, the extracts were super shifted with the indicated antibodies, with or without competition with ds DNA corresponding to the proximal half of the probe. Shifted bands are indicated by filled arrowheads and super shifted band are indicated by open arrowheads.

DETAILED DESCRIPTION OF THE INVENTION

The present invention relates to the promoter of human IL-18BP. This promoter drives the constitutive expression of IL-18BP in particular cells, for example monocytes and the IFN γ mediated induction of IL-18BP expression in many cells. The promoter of human IL-

18BP was found to be capable of directing the constitutive and IFN γ induced expression of a heterologous protein.

IL-18BP mRNA is detected in leukocytes, colon, small intestine, prostate and mainly in spleen cells (Növik et al.1999). In one of the examples below it was shown that IL-18 protein is constitutively expressed in monocytes.

IL-18BP expression was found to be induced by IFN γ , not only in monocytes but also in many different cells and that this induction could be further enhanced by the addition of IL-6 and TNF α .

- 10 *De novo* protein synthesis was found to be essential for IL-18BP gene activation by IFN γ .

The transcription start site of human IL-18BP α mRNA was determined by 5' RACE.

The 3' end mRNA of the Zn finger protein located upstream of the IL-18BP gene was found thereby limiting the potential upstream regulatory sequence of the IL-18BP α to 1601 bases upstream of base 1.

Six regulatory elements (Figure 1) were identified within this region (from the transcription proximal to the transcription distal): 1- A gamma-activated sequences (GAS) at bases -24 to -32, 2- An IRF-1,2 response element (IRF-E) spanning bases -57 to -69, 3- and 4- two C/EBP β response elements at bases -309 to -322 and -621 to -634, 5- a silencer at residues -625 to -1106 and 6- an enhancer element spanning bases -1106 to -1272. A series of luciferase reporter vectors with progressive truncations at the 5' end of the 1601 bp fragment were tested in HepG2 cells (a human hepatocellular carcinoma line). The 1272 kb region (SEQ ID NO: 1) appears to direct both, a basal expression seen in some tissues and cell types, as well as induction by IFN γ . Testing promoter activity on successive truncated DNA fragments within this region demonstrated that a 122 bp DNA fragment (SEQ ID NO: 3), proximal to the transcription start site is the minimal promoter. This minimal promoter is also inducible. However, other regulatory sequences upstream of this minimal promoter did contribute to the extent of induction. A DNA fragment of 635 bp (SEQ ID NO: 2), containing in addition to the IRF-1 and GAS

elements two C/EBP β elements, was found to confer maximal induction of luciferase expression by IFN γ .

In-vivo experiments carried out with IRF-1-deficient mice confirmed the importance of IRF-1 as a mediator of basal as well as IFN γ -induced expression of IL 18BP.

- 5 It was found that upon IFN γ induction, the expression of the IRF-1 factor is induced and the factor is complexed to C/EBP β which is constitutively present in the cells. The complex binds to the proximal GAS promoter element and its adjacent IRF-E promoter element.

- 10 The enhancer present at the transcription site distal end was found to interact with the basal promoter through IRF-1.

- 15 The present invention relates to the IL18BP promoter of SEQ ID NO:1 and methods for regulating gene expression. More particularly, the present invention relates to the isolated DNA sequences of IL-18BP 1272 bp (SEQ ID NO:1), 635 bp (SEQ ID NO: 2) and 122bp (SEQ ID NO: 3) upstream of the transcription start site of IL-18BP which are capable of directing gene expression.

- 20 The promoter region of the present invention comprises the promoter region of the IL-18BP gene. This IL-18BP promoter region has been cloned and sequenced and corresponds to nucleotides in the 1272 bp upstream of the transcription start site of IL-18BP (SEQ. ID. NO: 1) as shown in FIG 2.

- 25 The present invention encompasses the entire IL-18BP promoter region (SEQ ID NO:1, but also DNA sequences comprising a fragment thereof, IL-18BP promoter (SEQ ID NO:2). Both capable of directing gene transcription, and therefore ultimately gene expression, and can be used with other portions of the IL-18BP promoter region or alternatively with heterologous promoters or heterologous promoter elements to control gene transcription. These promoters are capable of induction by IFN γ . Such induction

can be further enhanced by overexpression of IRF-1 and/or C/EBP β and/or by treatment with IL-6 and/or TNF α

Functional derivatives of SEQ ID NO:1, SEQ ID NO:2 and SEQ ID NO:3 are DNA
5 fragments thereof which are capable of directing gene expression and IFN γ induction.

The DNA sequences of the present invention comprising a IL-18BP promoter region (SEQ ID NO: 1 Figure 2) or a IL-18BP promoter (SEQ ID NO:2) can be obtained using various methods known in the art. At least three alternative principal methods may be
10 employed:

(1) the isolation of the DNA sequence from genomic DNA which contains the sequence;
(2) the chemical synthesis of the DNA sequence; and (3) the synthesis of the DNA sequence by polymerase chain reaction (PCR).

15 In the first approach, a human genomic DNA library can be screened in order to identify a DNA sequence comprising a IL-18BP promoter or IL-18BP promoter element.

In the second approach, a DNA sequence comprising a IL-18BP promoter or a IL-18BP
20 promoter element can be chemically synthesized. For example, a DNA sequence comprising a IL-18BP promoter region or a IL-18BP promoter can be synthesized as a series of 100 base oligonucleotides that can then be sequentially ligated (via appropriate terminal restriction sites) so as to form the correct linear sequence of nucleotides.

25 In the third approach, a DNA sequence comprising a IL-18BP promoter region or a IL-18BP promoter can be synthesized using PCR. Briefly, pairs of synthetic DNA oligonucleotides at least 15 bases in length (PCR primers) that hybridize to opposite strands of the target DNA sequence can be used to enzymatically amplify the intervening region of DNA on the target sequence. Repeated cycles of heat denaturation of the
30 template, annealing of the primers and extension of the 3'-termini of the annealed primers

with a DNA polymerase results in amplification of the segment defined by the 5' ends of the PCR primers. See, U.S. Pat. Nos. 4,683,195 and 4,683,202.

The IL-18 BP promoter region and promoter were shown to be capable of conferring basal expression and also induced expression by IFN γ of an heterologous gene. Thus, the
5 promoter region and promoter of IL-18BP have both basal and inducible activity.

While the nucleotide sequence of the promoter region is shown in FIG. 2 (-SEQ. ID. NO.1) and the promoter (SEQ ID NO:2) and reference is made to such sequence in the specification, it is recognized that nucleotide modifications can be made which do not
10 affect the promoter or promoter element function. These modified nucleotide sequences may be prepared, for example, by mutating the nucleotide sequence so that the mutation results in the deletion, substitution insertion, inversion or addition of one or more nucleotides using various methods known in the art. For example, the methods of site-directed mutagenesis described in Taylor, J. W. et al., Nucl. Acids Res. 13, 8749-8764
15 (1985) and Kunkel, J. A., Proc. Natl. Acad. Sci. USA 82, 482-492 (1985) may be employed. In addition, kits for site-directed mutagenesis may be purchased from commercial vendors. For example, a kit for performing site-directed mutagenesis may be purchased from Amersham Corp. (Arlington Heights, Ill.). A preferred modified nucleotide of the IL-18BP promoter consist of the 122 bp DNA sequence upstream of the
20 transcription start site of IL-18BP (EQ ID NO:3). The present invention encompasses DNA containing sequences at least 50% identical and preferably 75% identical and more preferably 90% identical to SEQ ID NO:1, SEQ ID NO:2 and SEQ ID NO:3 provided that the regulatory elements in SEQ ID NO:1 (elements 1 to 5 figure 1), SEQ ID NO:2 (elements 1-3 Figure 1) and SEQ ID NO:3 (elements 1 and 2 Figure 1) are retained.

25
The nucleotide sequence comprising the promoter region or promoter of IL-18BP or modified nucleotides can be operably linked to the coding region of any gene of interest to express that gene in an appropriate host cell. By operably linked is intended operably
30 linked for promoter and elements. For expression of a gene of interest, it is preferred that the entire IL-18BP promoter region (nucleotides of SEQ. ID. NO.1: as shown in FIG.) or

the promoter itself (SEQ ID 2) or a modified nucleotide sequence thereof, such as SEQ ID 2, be operably linked to the gene of interest. As shown below in the example section, the IL-18BP promoter is capable of directing the expression of heterologous genes, the expression of homologous genes is also contemplated.

5

The promoter may further contain an intron, for example the first intron of IL-18BP.

10 An "operably linked" IL-18BP promoter or promoter element will direct the transcription of a nucleic acid molecule joined in proper reading frame. With regard to heterologous promoters, the promoters and elements of the invention are operably linked when they control the function of such heterologous promoters.

15 As noted above, the IL-18BP promoter region, the promoter, and modified nucleotide sequences thereof of the present invention can be utilized to express any gene of interest. Typically, an expression vector is used for this purpose. Thus, the present invention further concerns expression vectors comprising an isolated DNA sequence capable of directing gene expression which comprises a IL-18BP promoter or a IL-18BP promoter element. The expression vectors preferably contain a IL-18BP promoter region, promoter or modified nucleotide sequence thereof having a
20 nucleotide sequence corresponding to SEQ ID NO:1, SEQ ID NO:2 or SEQ ID NO:3, respectively. Also preferred are expression vectors further comprising a homologous or heterologous gene operatively linked to the IL-18BP promoter region or the IL-18BP promoter or modified nucleotide sequence thereof .

25 Expression vectors of utility in the present invention are often in the form of "plasmids", which refer to circular double stranded DNAs which, in their vector form, are not bound to the chromosome. However, the invention is intended to include such other forms of expression vectors which serve equivalent functions and which become known in the art subsequently hereto.

Expression vectors useful in the present invention typically contain an origin of replication, a IL-18BP promoter or a IL-18BP promoter element located in front of (i.e., upstream of) the gene of interest, transcription termination sequences and the remaining vector. The expression vectors can also include other DNA sequences known in the art, for example, stability leader sequences which provide for stability of the expression product, secretory leader sequences which provide for secretion of the expression product, sequences which allow expression of the structural gene to be modulated (e.g., by the presence or absence of nutrients or other inducers in the growth medium), marking sequences which are capable of providing phenotypic selection in transformed host cells, and sequences which provide sites for cleavage by restriction endonucleases. The characteristics of the actual expression vector used must be compatible with the host cell which is to be employed. An expression vector as contemplated by the present invention is at least capable of directing the transcription, and preferably the expression, of the gene of interest dictated by the IL-18BP promoter region or IL-18BP promoter or a modified nucleotide sequence thereof. Suitable origins of replication include, for example, that of the Simian virus 40 (SV40). Suitable termination sequences include, for example, that of the Simian virus 40 (SV40). The promoter of the invention can be employed for the expression of virtually any gene of interest, for example, those encoding therapeutic products such as interferon-beta, TNF, erythropoietin, tissue plasminogen activator, granulocyte colony stimulating factor, manganese-superoxide dismutase, an immunoglobulin, or fragment thereof, growth hormone, hsLDLR, FSH, hCG, IL-18, TNF receptor binding proteins and IL-18 binding proteins. All of these materials are known in the art and many are commercially available.

Suitable expression vectors containing the desired coding and control sequences may be constructed using standard recombinant DNA techniques known in the art, many of which are described in Sambrook, et al., Molecular Cloning: A Laboratory Manual, 2nd edition, Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y. (1989).

The present invention additionally concerns host cells containing an expression vector comprising an isolated DNA sequence capable of directing gene expression which comprises a IL-18BP promoter region or a IL-18BP promoter or modified nucleotide sequences thereof. Preferably, the IL-18BP promoter region has the nucleotide sequence corresponding to 1272 bp upstream of the transcription start site of IL-18BP gene (SEQ ID NO:1) as shown in Fig. , the IL-18BP promoter has the nucleotide sequence corresponding to 635 bp upstream of the transcription start site (SEQ ID NO: 2) and modified promoters such as that corresponding to the nucleotide sequence of 122 bp upstream of the transcription start site (SEQ ID NO:3) . Also preferred are host cells containing an expression vector further comprising a homologous or heterologous gene operatively linked to the IL-18BP promoter region or the IL-18BP promoter or the modified promoter. Suitable host cells include, for example, human HeLa cells or African Green Monkey cells CV-1 and COS-1, CHO cells, HepG2, WISH cells, Hakat U937 etc.

Preferred are host cells containing receptors for IFN γ , which allow induction of the IL-18BP promoter and therefore enhanced expression of the gene of interest.

Expression vectors may be introduced into host cells by various methods known in the art. For example, transfection of host cells with expression vectors can be carried out by the calcium phosphate precipitation method. However, other methods for introducing expression vectors into host cells, for example, electroporation, biolistic fusion, liposomal fusion, nuclear injection and viral or phage infection can also be employed.

Once an expression vector has been introduced into an appropriate host cell, the host cell can be cultured and the polypeptide encoded by the gene of interest can be isolated. Alternatively once an expression vector has been introduced into an appropriated host cell, the cell can be cultured and after reaching a desired cell density, the cells can be stimulated with IFN γ and the polypeptide encoded by the gene of interest can be isolated.

Host cells containing an expression vector which contains a DNA sequence coding for a gene of interest may be identified using various methods known in the art. For example, DNA-DNA hybridization, assessing the presence or absence of marker gene functions, assessing the level of transcription as measured by the production of mRNA transcripts of the gene of interest in the host cell, and detecting the gene product immunologically can be employed.

The DNA sequences of expression vectors, plasmids or DNA molecules of the present invention may be determined by various methods known in the art. For example, the dideoxy chain termination method as described in Sanger et al., Proc. Natl. Acad. Sci. USA 74, 5463-5467 (1977), or the Maxam-Gilbert method as described in Proc. Natl. Acad. Sci. USA 74, 560-564 (1977) may be employed.

It should be understood specific nucleotides or regions within the IL-18BP promoter region or IL-18BP promoter may be identified as necessary for regulation. These regions or nucleotides may be located by fine structural dissection of the elements, and can be studied by experiments which analyze the functional capacity of promoter mutants. For example, single base pair mutations of promoter elements or progressive deletions, as such employed in the example section below, can be generated utilizing PCR. In this fashion, a number of mutated promoter regions or deletion constructs are amplified, and then cloned back into reporter constructs and evaluated with transfection and luciferase assay techniques (as set forth in the example section below). These amplified fragments can be cloned back into the context of the IL-18BP promoter and also into the heterologous promoter constructs. In this fashion, the exact nucleotide sequences that are important in directing gene transcription are identified.

This analysis will also identify nucleotide changes which do not effect promoter function, or which may increase promoter function. Thus, functional derivative promoters and promoter elements can also be constructed.

Functional analysis of the promoter region can be facilitated by footprint and gel-shift studies. Knowledge of the exact base pairs important in mediating binding of proteins provides evidence of bases important in mediating the transcriptional response.

5 The invention therefore further encompasses the base pairs important in DNA-protein interaction. Such base pairs can be elucidated. Genomic fragments containing the areas of interest can be employed in in vitro footprinting experiments [Galas et al., Nucleic Acids Res. 9, 6505-6525 (1981)]. Isolated restriction fragment can be radiolabeled and subsequently incubated with nuclear extracts made with established techniques from cells expected to contain DNA binding proteins which will bind to the fragment [for example, Dignam et al., Nucleic Acids Res. 11, 1475-1489 (1983)]. Labeled DNA fragments are incubated with the nuclear extracts, digested with DNase I, and electrophoresed on a denaturing polyacrylamide gel. DNA binding proteins in the cell extract bind to their recognition sequence contained in the labeled restriction fragment, and protect the DNA from digestion by the DNase. Regions of protection delineate the binding site. Maxam and Gilbert sequencing reactions of the fragment can be used as a marker to define the nucleotides protected from DNase digestion.

20 The invention is further drawn to the identification and characterization of trans-acting factors which interact with the promoter or promoter elements. Cis-acting regulatory sequences serve as binding sites for proteins which are termed transacting factors (TAF) [Dyan W. S., Tjian T. Nature 316, 774-778 (1985); Maniatis, T. et al., Science 236, 1237-1245 (1987)]. Each gene is presumed to bind one or more proteins at each of its regulatory sequences, and these proteins interact with one another and RNA polymerase II in a fashion that controls transcription.

TAFs have been identified in nuclear extracts by their ability to bind to and retard electrophoretic mobility of cis-acting sequence DNA fragments [Dignam, J. D. et al., Nucleic Acids Res. 11, 1475-1489 (1983); Dyan, W., Cell 58, 1-4 (1989); Fletcher, C. et al., Cell 773-781 (1987); Scheidereit, C. et al., Cell 51, 783-793 (1987)].

The cis-acting sequences are useful in gel retardation assays to determine binding activity in nuclear extracts. The technology for gel shift assays is described in the literature and includes many of the same reagents used in footprint experiments [Fried, M. et al., *Nucleic Acids Res.* 9, 6505-6525 (1981); Revzin, A., *Biotechniques* 7, 346-355 (1989); Strauss, F. A. et al., *Cell* 37, 889-901 (1984)]. Either 32 P-labeled restriction fragments or annealed pairs of complementary oligos are incubated with nuclear extracts and poly d(I-C) in a binding buffer, and the products of this reaction electrophoresed on a non-denaturing polyacrylamide gel. The location of the DNA fragment on the gel as determined with autoradiography is retarded in cases where protein has bound to the DNA. The extend of the retardation is a relative function of the size of the protein.

The binding proteins so identified can then be purified and ultimately cloned using known techniques.

The promoter region of IL-18BP and promoter of IL-18BP also find use in transgenic studies. Transgenic mice provide a powerful genetic model for the study of a number of human diseases including cancer. They have also provided an important in vivo method for studies of gene regulation that have confirmed and extended observations made with transfection reporter gene (e.g. luciferase)experiments [Palmiter, F. L. et al., *Ann. Rev. Genet.* 20, 465-499 (1986)]. Studies aimed at dissecting the signals allowing developmental relation of gene expression can rarely be performed in cell culture models and is probably best studied with a transgenic model. This type of experiment is possible because of the remarkable conservation between species of regulatory sequences, such that human regulatory signals are accurately interpreted by the mouse transcription machinery.

Constructs expressed in transgenic mice could therefore provide much information about the regulation of the IL-18BP gene.

Transgenic mice can be made by methods known in the art. The most widely used method through which transgenic animals have been produced involve injecting a DNA molecule into the male pronucleus of a fertilized egg [Brinster et al., Cell 27, 223 (1981); Costantini et al., Nature 294, 982 (1981); Harpers et al., Nature 293, 540 (1981); Wagner et al., Proc. Natl. Acad. Sci. USA 78, 5016 (1981); Gordon et al., Proc. Natl. Acad. Sci. USA 73, 1260 (1976)].

Once the DNA molecule has been injected into the fertilized egg cell, the cell is implanted into the uterus of recipient female and allowed to develop into an animal. Thus, all of the cells of the resulting animal should contain the introduced gene sequence.

The resulting transgenic mice or founders can be bred and the offspring analyzed to establish lines from the founders that express the transgene. In the transgenic animals, multiple tissues can be screened to observe for gene expression. RNA studies in the various mouse lines will allow evaluation of independence of the integration site to expression levels of the transgene. See, Hogan, B. et al., Manipulating the mouse embryo: a laboratory manual, Cold Spring Harbor Press, Cold Spring Harbor, N.Y. (1986).

The IL-18BP promoter and promoter elements may also provide a useful means for carrying out gene therapy.

"Gene therapy " is the administration of genetic material to modify or manipulate the expression of a gene product to alter biological properties of living cells for therapeutic use.

The cells can be allogeneic or autologous. Cells may be modified ex-vivo for subsequent administration to the subject or altered in vivo by gene therapy products given directly to the subject.

For the most part, constructs comprising the IL-18BP promoter region or IL-18BP promoter or modified promoter will be utilized to target gene expression in those cells when the IL-18BP gene is normally expressed, for example mononuclear cells.

Any means available in the art for transfer of the constructs into animals, including humans, can be utilized. This includes viral vectors, particularly retroviral vectors (see, for example, Zweibel et al, Science 243, 220 (1989), and the references cited therein), as well as other methods.

5

Recombinant AAV vectors have been shown quite promising for therapeutic gene delivery in liver and skeletal muscle (Snyder et al. 1997, Murphy et al. 1997, Song et al. 1998, Snyder et al. 1999, Herzog et al. 1997). Mice generated by disrupting the clotting factor IX gene exhibit severe bleeding disorder and closely resemble the phenotype seen in hemophilia B patients. It has been reported (Wang et al. 1999) that a single intraportal injection of a recombinant adeno-associated virus (AAV) vector encoding canine factor IX cDNA under the control of a liver-specific enhancer/promoter leads to a long-term and complete correction of the bleeding disorder.

10

15

Retroviral vectors, derived from oncoretrovirus such as the murine leukemia virus (MLV), have been the most widely used vectors for gene transfer because the vector genome integrates into the chromosomes of target cells, resulting in stable expression of transgenes (I.M. Verma and N. Somia. Nature 389, 239 (1997) however these vectors were proven to be good especially for dividing cells. Lentiviruses such as HIV vectors are being currently used for nondividing cells. Mioshi et al. Science 1999 283: 682-686. The ability of lentiviruses to infect nondividing cells such as macrophages makes them good candidates for use as gene transfer tools. HIV vectors facilitate transduction of quiescent human hematopoietic stem cells (HSCs).

20

25

Human hematopoietic stem cells (HSC) are an attractive target for gene therapy of inherited hematopoietic disorders as well as other acquired disorders because these cells have the ability to regenerate the entire hematopoietic system. For example hematopoietic stem cells can regenerate monocytic cells which are known to be involved in human immunodeficiency virus-1 (HIV-1) pathogenesis.

30

Despite more than 15 years of research in the field of gene therapy using hematopoietic stem cells, the major hurdle remains the inability to efficiently and stably insert genes into these cells. Retroviral vectors based upon the Moloney murine leukemia virus (MLV) have been used most extensively, but yield relatively low gene transfer into pluripotent human HSC and gene expression which is often unsatisfactory.

Recently, attempts of genetic modification of hematopoietic stem cells with genes that inhibit replication of HIV-1 are aimed, for the development of monocytes resistant to HIV-1 infection (Kohn et al. 1999).

Theoretically, insertion of a gene capable of conferring resistance to HIV-1 into hematopoietic stem cells would result in that gene being present in the descendant mature monocytes and other HIV-1 susceptible cells

Thus, the use of a promoter which is active in monocyte cells such as the promoter region of IL-18BP and the promoter of IL-18BP and modified promoters thereof, for HIV-1 gene therapy is advantageous.

Gene therapy of most blood genetic disorders (e.g. SCID chronic granulomatous disease, thalassemia etc.) requires ex vivo gene transfer into transplantable, self renewing HSCs and regulation of transgene expression in one or more cell lineages.

Correction of disorders affecting a specific progeny of HSCs (e.g. hemoglobinopathies or thalassemias, HIV-1infection) requires restricting expression of therapeutic gene in cell lineage specific fashion (lotti et al. 2002). In these cases, transcriptional targeting of the transferred gene is mandatory. Gene expression in different cell types is dependent on the relative strength of the promoter used. However, most preclinical studies carried out so far have relied on the use of viral, constitutive promoters to drive transgene expression. For example in HIV-1 vector uses an internal CMV promoter and the murine CMV promoter the murine retroviral vector LTR. Appropriate transgene regulation in the framework of a retroviral vector is a difficult task, due to transcriptional interference between the viral long terminal

repeat (LTR) and internal enhancer-promoters and genetical instability of complex regulatory sequences. In the present invention the promoter of IL-18BP which is known to drive transcription in mononuclear cells is used to drive transgene expression in HSCs, the precursor of such mononuclear cells.

5 Genetic modification of hematopoietic stem cells with "anti HIV genes " could lead to development of lymphocytes and monocytes resistant to HIV infection after transplantation. HSC of HIV-1 infected patients can be recovered, CD34+ cells isolated, transduced in vitro with a retroviral vector carrying an HIV-1 inhibitory protein under the control of the IL-18BP promoter (instead of the retroviral
10 promoter) and reinfusing these cells into these patients (Kohn et al. 1999).

The most commonly used source of HSC is peripheral blood hematopoietic stem cells (PBSC), which have largely replaced bone marrow in the setting of autologous transplantation (Gale et al. 1992 and Kessinger et al. 1991). PBSC are mobilized from the bone marrow into the peripheral circulation by administration of factors such as
15 G-CSF or GM-CSF for 3-5 days and can then be collected by leukapheresis. Several studies have shown that engraftment occurs faster when transplanting peripheral blood stem cells instead of bone marrow (Henon et al 1992 and Chao et al. 1993). The clonogenic progenitor cells contained in G-CSF-mobilized PBSC are quite susceptible to retroviral-mediated gene transfer, whereas the transduction rate of
20 long-term reconstituting stem cells in PBSC is no better than bone marrow (Breni et al. 1992, Cassel et al. 1993, Dunbar et al. 1995). It has been shown that HIV-1 infected subjects can have successful mobilization and collection of G-CSF-mobilized PBSC without any increase in endogenous HIV-1 levels, at least during early stages of disease (Junker et al. 1997 and Slobod et al. 1996).

25 Another source of hematopoietic stem cells is umbilical cord blood (UCB) which has been shown to be susceptible to retroviral transduction, potentially even more so than bone marrow cells (Moritz et al. 1993 and Hao et al. 1995). Use of UCB cells HSC could be particularly beneficial for HIV-1 infected neonates. Since transmission is mostly perinatal, the umbilical cord blood should contain normal numbers and
30 function of hematopoietic stem cells, which may be diminished in the bone marrow of HIV-1 infected children and adults (Kearns et al. 1997).

A large number of synthetic genes have been developed which can suppress HIV-1 replication ("anti-HIV-1 genes"), including: antisense, ribozymes, dominant-negative mutants (e.g. RevM10), RNA decoys, intracellular antibodies to prevent expression of viral proteins or cellular co-receptors, etc. (Veres et al. 1996, Zhou et al. 1994, Couture et al 1996, Malim et al. 1989, bahner et al 1993 and Sullenger et al. 1990, Lee et al. 1994, Marasco et al 1997 and Chen et al. 1997). In many cases, these anti-HIV-1 genes have been shown in model systems to be able to significantly suppress the replication of HIV-1 and in some cases even limit virus entry into cells (36, 39-44). If essentially 100% of a patient's HSC and the resultant monocytic cells could be made incapable of supporting HIV-1 replication, it is likely that decreased viral burdens would result. Theoretically, active inhibition of HIV-1 replication in 99.9% of the susceptible cells would be required to produce a 3-log reduction in virus load, an effect often produced by highly-effective anti-retroviral therapy. However, with the limited capabilities to effectively transduce high percentages of human hematopoietic stem cells, it is not currently possible to protect the majority of susceptible cells. An alternative mechanism for efficacy is based on the possibility that cells engineered to be incapable of supporting active HIV-1 replication may be protected from viral-induced cytopathicity and thus have a selective survival advantage compared to non-protected cells. In that case, a modest number of protected cells may comprise an increased percentage of all monocytes, leading to some preservation of immune function.

The present invention also relates to pharmaceutical compositions comprising a pharmaceutically acceptable carrier and a virus comprising a sequence of the present invention corresponding to the IL-18BP promoter region or promoter operably linked to a gene of interest encoding for a suitable drug. These compositions may be used preferably for targeting a drug to tissues in which the levels of IFN γ are elevated.

Having now described the invention, it will be more readily understood by reference to the following examples that are provided by way of illustration and are not intended to be limiting of the present invention.

EXAMPLES

Example 1:

Basal expression of IL-18BP in monocytes.

- 5 IL-18BP mRNA is detected in leukocytes, colon, small intestine, prostate and particularly in spleen cells (Novick et al.1999). Spleen cells consist of macrophages, lymphocytes, and plasma cells with additional cells derived from the circulation.

In order to determine expression of IL-18BP protein in cells, a specific ELISA test was used (Example 12). Human peripheral blood mononuclear cells (PBMC) were found to
10 constitutively produce IL-18BP (0.7-1.5 ng/ml). U-937 cells, a cell line derived from malignant cells obtained from the pleural effusion of a patient with histiocytic lymphoma, did not express any IL-18BP. U-937 cells can be induced to terminal monocytic differentiation by treatment with phorbol esters. A basal IL-18BP expression of 0.07 ± 0.01 ng/ml was detected only after differentiation of the cells into macrophage-like cells by
15 stimulation with TPA (10ng/ml). These results show that IL-18BP is constitutively produced in monocytes and macrophages.

Example 2:

Induction of IL-18BP expression in various different cells.

- 20 It has been previously reported that IFN γ induced IL-18BP mRNA and protein in various cell lines such as a keratinocyte cell line, a colon carcinoma cell line and in primary renal mesangial cells (Muhl et al. 2000). The induction of IL-18BP in various human cell lines and in peripheral blood mononuclear cells (PBMC) by IFN γ and other cytokines was studied. IFN γ induced IL-18BP expression (see Example 11 for monitoring mRNA and
25 Example 12 for ELISA) in a dose-dependent manner, exhibiting an EC₅₀ at 50 U/ml in WISH and HepG2 cells (Figure 2 A and B). IL-18BP apparently accumulated in the culture supernatants of WISH cells, as its concentration was higher at 48 h compared with 24 h (Figure 2 A).

Human peripheral blood mononuclear cells (PBMC) constitutively produced IL-18BP (0.7-1.5 ng/ml), and treatment with IFN γ (100 U/ml) increased the level of IL-18BP by 1.7 ± 0.1 and 2.1 ± 0.3 fold at 24 and 48 h, respectively ($p < 0.05$, $n = 4$). No effect on IL-18BP production was seen upon pre-treatment of the PBMC with TPA.

- 5 IL-18BP induction by IFN γ was tested in the U937 cell line. IFN γ did not induce IL-18BP in undifferentiated U937 cells, however, following differentiation with phorbol ester (TPA, 10 ng/ml) into macrophage-like cells, a basal level of IL-18BP (0.07 ± 0.01 ng/ml) was obtained, and increased by 4.6 ± 0.05 fold upon induction with IFN γ (100 U/ml, 24 h), further increasing at 96 h (not shown).
- 10 The effect of other cytokines, such as IFN α_2 , IFN β , IL-1, IL-6, IL-12, IL-18 and TNF α , on IL-18BP expression was tested in HepG2 cells (Figure 2B). The results obtained following incubation of the cells with the different cytokines in the presence or the absence of IFN γ (Fig. 1 PNAS web) show that IFN α_2 , IFN β , IL-1, IL-6, IL-12, IL-18 and TNF α did not induce IL-18BP alone. However, in HepG2 cells IL-6 and TNF α acted
- 15 synergistically with IFN γ , providing a statistically significant increase of IL-18BP.

These results indicate that IL-18BP can be induced by IFN γ , in monocytes and in many different cells. Induction of IL-18BP by IFN γ is further enhanced by the addition of IL-6 and TNF α .

20

Example 3:

The IL-18BP gene is transcriptionally regulated by IFN γ , requiring *de novo* protein synthesis.

- 25 In order to check whether the induction of IL-18BP mRNA by IFN γ is at the transcriptional level, the effect of interferon on HepG2 and Wish cells was measured in the presence of a translation inhibitor, Actinomycin D (Fig. 3A). Increase in IL-18BP mRNA levels were detectable by semi-quantitative RT-PCR after 3 h of treatment with IFN γ in HepG2 cells and only after 5 h in Hakat and WISH cells. Pre-treatment of HepG2 and

WISH cells with Actinomycin D prior to IFN γ stimulation abolished the expression of IL-18BP mRNA at various time points, indicating that IFN γ stimulates de-novo mRNA synthesis.

- 5 Accumulation of IL-18BP was apparent 24 h and later following IFN γ treatment, supporting a dependence of IL-18BP expression on preceding induction of proteins, e.g. transcription factors, by IFN γ . Therefore in order to confirm such hypothesis, a protein inhibitor, cycloheximide, was further employed to test whether induction of IL-18BP mRNA by IFN γ requires de-novo synthesis of proteins. The results summarized in Figure
- 10 3B show that pre-treatment of the cells with cycloheximide abolished the induction of IL-18BP mRNA. This result indicates that *de novo* protein synthesis is essential for IL-18BP gene activation by IFN γ .

Example 4:

- 15 **Defining the transcription start site of IL-18BP α and its promoter region, in order to map the IL-18BP promoter.**

In order to study the IL-18BP promoter region, it is required first to specifically locate the transcription start site.

- 20 The transcription start site of human IL-18BP α mRNA was determined by 5' RACE (RACE Example 14). Only one PCR product, corresponding to IL-18BP α , the most abundant splice variant, was obtained by 5' RACE. DNA sequence analysis of this product revealed the transcription start site and an additional exon of 50 bp following the transcription start site at the 5'-end of human IL-18BP α mRNA, corresponding to positions 785-835 of the genomic IL-18BP DNA (can be found in the Entrez pubmed nucleotide
- 25 database, accession No. AF110798). Accordingly, a new exon-intron map was generated by comparing the genomic DNA with the mRNA to which the new 5' exon was added. (See Fig. 4).

Having the transcription start site of IL-18BP α (base 1), the human genomic DNA upstream of base 1 (chromosome 11q clone:RP11-757C15, Accession No AP000719.4

nucleotides upstream of base 152,178) corresponding to the IL-18BP promoter region could be further analysed. Comparison of this DNA to the expressed sequence tag (EST) database at NCBI by the BLAST program revealed an upstream gene at the + strand, coding for a Zinc-finger protein (Accession No. AK001961). The deposited mRNA sequence of this Zn finger protein was further elongated by the "Instant RACE" program (www.LabOnWeb.com), which scanned an extensive collection of human ESTs. The program placed the 3' end mRNA of the Zn finger protein at nucleotide 150,517 of the genomic clone RP11-757C15, thereby limiting the potential upstream regulatory sequence of the IL-18BP α to 1661 bases upstream of base 1 (Fig. 4).

10

Example 5:

Exploring the minimal promoter, upstream of the IL-18BP gene, capable for promoting constitutive expression of a heterologous gene.

15 In order to find the minimal DNA fragment, upstream of the IL-18BP gene, capable of directing expression of an hexogenous gene such as the luciferase reporter gene, a vector containing up to 1601 bp corresponding to the DNA sequence upstream of base 1 and including 50 bp downstream of the transcription start site (SEQ ID NO:1) and vectors having truncated forms of this DNA (Fig. 5A) fused to the luciferase gene were generated (Example 15). Luciferase activity in human HepG2 cells (a human hepatocellular carcinoma line) transfected with a vector (pGL3(1601)) comprising the 1601 bp upstream DNA (SEQ ID NO: 4) was 10.3 ± 0.9 fold higher than that obtained with the empty pGL3 vector. Such activity was not observed when the same DNA was inserted in the opposite orientation (pGL3(-1601)). This result demonstrated that the 1601 bp DNA upstream of base 1 has basal promoter activity. Sequence examination of this 1601 bp DNA fragment revealed that it does not include a TATA box element, but had several GC-rich domains near the transcription start site at bases -3 to -9, -39 to -48 and -122 to -132. Analysis of the 1601 bp DNA sequence by the program TFSEARCH identified a gamma-activated sequence (GAS) at bases -24 to -32 (Fig. 1). Further analysis revealed an IRF1,2 response

20

25

element (IRF-E) spanning bases -57 to -69 and two C/EBP β response elements (C/EBP-E) at bases -309 to -322 and -621 to -634.

A series of luciferase reporter vectors with progressive truncations at the 5' end of the 1601 bp fragment were tested. The results summarized in figure 5A show that all constructs, including pGL3 (122), containing only the IRF and GAS elements, were at least as effective as pGL3(1601) in supporting basal promoter activity.

These results revealed that the 122 bp fragment (SEQ ID NO:3) comprising the IRF and GAS elements are sufficient for promoting basal activity of an heterologous gene (Fig. 5A).

Example 6:

Exploring the minimal promoter, upstream of the IL-18BP gene, capable for promoting inducible expression of a heterologous gene.

In order to identify the minimal DNA fragment, upstream region of the IL-18BP promoter, capable of promoting IFN γ induced luciferase expression, the truncated DNA vectors from the preceding example were tested in transfected HepG2 cells in the presence of IFN γ (Figure 5B for transfections see example 16).

The results summarized in figure 5B show that after 24 h IFN γ increased the luciferase activity by 33 fold over the basal expression level in the vector including only IRF-E and GAS elements (pGL3(122) vector). This result demonstrates that the IRF-E-GAS pair alone can mediate heterologous gene induction by IFN γ . Inclusion of C/EBP-E1 and 2 elements (pGL3(656)) significantly increased the induction of luciferase activity by IFN γ to 88 fold over the basal activity, demonstrating the importance of these elements in inductivity by IFN γ . In contrast, inclusion of an additional upstream DNA to such insert (pGL3(1106)) abolished the induction of luciferase activity above its basal level. This

result suggested that a silencer element resides within bases -656 to -1106 (Upstream of the second C/EBP-E1 element). Further extension of the promoter by 88 bases upstream the silencer (pGL3(1272)) restored the response to IFN γ , suggesting that an enhancer element resides in bases -1106 to -1272, and its activation by IFN γ suppresses the effect of the neighboring silencer. Further extension of the sequence did not affect basal or IFN γ -induced activity, suggesting that all upstream regulatory sequences were located within bases -1 to -1272 (SEQ ID NO:1).

From all of the constructs tested the inductivity of the pGL3(656) is the highest, indicating that this DNA fragment contains the optimal inducible promoter of IL-18BP.

The results show that the minimal inducible promoter is located 122 bp upstream of the transcription start site (SEQ ID NO:3) containing the IRF-E and GAS elements, wherein the maximal and optimal inducible promoter is located 656bp upstream of the transcription start site (SEQ ID NO: 2) containing in addition to the IRF-E and GAS elements, two C/EBP β elements.

Example 7:

Involvement of IRF-1 in IL-18BP expression in-vivo.

To explore the involvement of IRF-1, the binding site of which was found to be in the promoter of IL-18BP, in IL-18BP expression the expression of IL-18BP in IRF-1 deficient mice was studied.

The levels of IL-18BP were measured in IRF-1-deficient mice (Jackson laboratories, Bar Harbor ME) before and after administration of murine IFN γ and compared to those in control C57Bl/6 mice (Fig. 6). Basal serum IL-18BP in control C57Bl/6 mice was 9.1 ± 1.9 ng/ml and was significantly increased by IFN γ to 22.4 ± 2.2 ng/ml. In contrast, serum IL-18BP in IRF-1-deficient mice was below the limit of detection and increased to only 0.7 ± 1.15 ng/ml with IFN γ . This result confirmed the importance of IRF-1 as a mediator of basal as well as IFN γ -induced expression of IL 18BP.

Example 8:

Detection of the transcription factors binding to the IL-18BP promoter under inductive conditions.

Electrophoretic mobility shift assays (EMSA Example 18) were employed to identify protein-DNA interactions among the various response elements within the IL-18BP promoter. Labelled ds DNA probes corresponding to bases -33 to -75 (containing the IRF-E) and -8 to -55 (containing the GAS) were allowed to bind with nuclear extracts of control and IFN γ -treated cells. A complex of the IRF-E-containing probe and nuclear protein(s) was apparent following incubation of cells for 1 h with IFN γ and maximal response was seen at 3 h (Fig. 7 A, lanes 1-5). As expected, addition of antibodies to IRF-E caused a "super-shift", whereas control anti- signal transducer and activator of transcription 1 (STAT1) antibodies had no effect (data not shown). In contrast with IRF-E, the GAS-containing probe was constitutively associated with a protein (Fig. 7 A, lane 6) and this complex was enhanced upon induction of cells with IFN γ for 3 to 6 h (lanes 7,8). GAS is expected to bind the IFN γ -induced STAT1 dimer. Nevertheless, the complex was not affected by antibodies to STAT1 (lane 10), suggesting that the IFN γ -induced STAT1 dimer was not associated with this GAS. The same negative result was obtained with nuclear extracts of cells treated with IFN γ for only 15 or 30 min (data not shown). Surprisingly, this complex was abolished by antibodies to C/EBP β (lane 9) and was super shifted with antibodies to IRF-1 (lane 10). Hence the GAS-containing DNA probe appears to bind C/EBP β despite lack of a consensus C/EBP β E.

The results obtained with EMSA indicate that upon induction with IFN γ , IRF-1 binds to the IRF-E element in the IL-18BP promoter. In addition, a complex comprising IRF-1 and C/EBP β is formed and binds to the GAS element.

Example 9:

Exploring the role of the IRF-1-C/EBP β complex in IL-18BP induction.

To further study the role of IRF-1 and C/EBP β in IL-18BP gene induction, IL-18BP mRNA was measured by semi-quantitative RT-PCR following overexpression of IRF-1

and C/EBP β by employing transfection of expression vectors (Example 14, Fig. 7 B). Over-expression of either transcription factor or a combination of both factors in HepG2 cells did not induce IL-18BP mRNA. This result suggested that additional IFN γ -induced factors are required for activation of the IL-18BP gene. Transfection of the cells with either one of the expression vectors followed by their induction with IFN γ actually reduced IL-18BP mRNA compared with IFN γ alone. In contrast, co-expression of the two transcription factors increased the induction of IL-18BP mRNA by IFN γ . This result suggested that IRF-1 and C/EBP β must be present at a certain ratio, possibly forming a complex within the transcription initiation complex. To further study the possible interaction between IRF-1 and C/EBP β a titration of luciferase activity by co-transfecting cells with pGL3 (1272), a fixed amount of an IRF-1 expression vector and varying amounts of C/EBP β expression vector was performed. Similarly, luciferase activity when the C/EBP β vector was kept constant and with varying amounts of the IRF-1 vector was measured. In both cases a bell-shaped dose-response curve was obtained, suggesting that optimal IL-18BP induction requires a fixed molar ratio between these two transcription factors (Fig. 7 C).

Immunoprecipitation studies were carried out in order to confirm the physical association between IRF-1 and C/EBP β (Example 19, Fig. 7 D). Immunoprecipitation (ip) followed by immunoblotting (ib) of nuclear and cytoplasmic proteins (Example 15) from IFN γ -treated cells with antibodies to C/EBP β revealed that C/EBP β is constitutively expressed in HepG2 cells and translocates to the nucleus in response to IFN γ (upper panel). In contrast to C/EBP β which is not induced by IFN γ , ip and ib of cell extracts with antibodies to IRF-1 revealed that IFN γ induces the expression of IRF-1. But similar to C/EBP β , upon IFN γ induction, IRF-1 is translocated to the nucleus (middle panel). Ip with antibodies to C/EBP β followed by ib with antibodies to IRF-1 revealed the presence of a stable IRF-1-C/EBP β complex in the nuclear fraction (lower panel). These results confirm the formation of the IRF-1-C/EBP β complex upon IFN γ induction and is the first demonstration of the existence of such a complex between these two transcription factors. Thus upon IFN γ induction, the proximal GAS-containing sequence and its adjacent IRF-E bind the complex of C/EBP β and IRF-1.

Example 10:

Exploring the role of the C/EBP-Es in the IL-18BP promoter activity.

The two C/EBP β sites at positions -309 to -322 and -621 to -634 do not have an adjacent IRF-E. Indeed, EMSA (Example 18) of a probe corresponding to the C/EBP β sites at
5 positions -309 to -322 revealed a retarded band (filled arrowhead) that was super shifted with antibodies to C/EBP β (open arrowhead) but not with antibodies to IRF-1 (Fig. 8 A). Hence, it was concluded that this site binds C/EBP β and not its complex with IRF-1. Furthermore, this band was generated with a nuclear extract of un-induced HepG2 cells that constitutively express C/EBP β but lack IRF-1. In fact, IFN γ did not increase the
10 expression of C/EBP β in these cells (Fig. 8 D) and consequently it did not increase the intensity of the retarded band (Fig. 8 A). Similar results were obtained with the more distal C/EBP β site (data not shown).

The results show that the C/EBP transcription factor unlike the IRF-1, is constitutively expressed and not induced by IFN γ and that in addition of binding to IRF-1 and to GAS,
15 it binds to both of the C/EBP elements present in the IL-18BP promoter.

Example 11:

Studying the role of the enhancer in the expression of IL-18BP.

The regulatory role of the distal enhancer was studied by EMSA (Example 18) with a 192
20 bp DNA probe, corresponding to nucleotides -1081 to -1272. Nuclear extract of control HepG2 cells formed a complex with this probe (Fig. 8 B, filled arrowhead). Upon treatment of the cells with IFN γ , the complex was more intense and somewhat more retarded. A super-shift of this complex with antibodies directed against IRF-1, C/EBP β and cFos was then performed. Of these, only anti IRF-1 elicited a super-shift (Fig. 8 B, empty
25 arrowhead). An unlabelled dsDNA corresponding to nucleotides -1083 to -1174 did not compete with the radiolabeled probe, indicating that the nuclear proteins were bound to residues -1175 to -1272. Since IRF-E was identified only in the proximal region, this result suggests that the distal enhancer was probably associated with the proximal IRF-E.

These results indicate that the distal enhancer interacts with the basal promoter through IRF-1.

Example 12:

5 ELISA for IL-18BP.

Human IL-18BP was measured by a double antibody ELISA as described (Novick et al 2001). Mouse IL-18BP was measured by a double antibody ELISA using rabbit antigen affinity-purified polyclonal antibody to murine IL-18BP and biotinylated antibody that were obtained from Cytolab, Israel.

10

Example 13:

RNA isolation and Reverse Transcription (RT)-PCR.

Following treatment in serum-free medium, HepG2, and WISH cells (10^6) were harvested at the indicated times and total RNA was extracted using TRI reagent. cDNA was prepared using random hexamers and SuperscriptII (Invitrogen™, Leek, The Netherlands) according to the manufacturer's instructions. PCR was performed with the following primers: human IL-18BP, 5' CACGTCGTCACCTCTCCTGG and 5' CGACGTGACGCTGGACAAC; human IRF-1 5' GACCCTGGCTAGAGATGCAG and 5' GAGCTGCTGAGTCCATCAG; human β Actin 5' GTGGGGCGCCCCAGGCACCA and 5' CTCCTTAATGTCACGCACGATTTC.. Amplifications were done by initial denaturation (92°C, 2 min), 28 cycles of denaturation (92°C, 45 sec.), annealing (62°C, 1 min) and extension (72°C, 1.5 min), and final extension (72°C, 10 min). The resulting PCR products were resolved by agarose (1%) gel electrophoresis.

25

Example 14:

Rapid amplification of 5' cDNA ends (5' RACE).

5' RACE was performed with a 5' RACE System (GIBCO BRL) according to the manufacturer's instructions. Briefly, total RNA from IFN γ -treated WISH cells was

reverse-transcribed (Example 13) with a primer complementary to nucleotides 89 -70 of IL-18BP α mRNA (GenBank Accession No. AF110799) followed by tailing of the newly synthesized ends with an anchor DNA. PCR was then performed with a forward primer complementary to the anchor DNA and a nested reverse primer complementary to nucleotides 31 - 11 of IL-18BP α mRNA. The PCR products were then subcloned and subjected to DNA sequence analysis.

Example 15:

Plasmids and cloning.

The entire putative IL-18BP α promoter region of 1601 bp was obtained by PCR of genomic DNA using a sense primer (S4753.pgl) containing a Kpn I site (5' CTATATGGTACCCACCCTTCCTTTTACTTTTCC) and reverse primer (R1exA) containing Nhe I site (5' TATCGCTAGCCAGTCACACAGGGAGGCAGT). The PCR product was cloned into pGEM-T Easy vector (Promega, Madison, WI) and verified by DNA sequence analysis. A Kpn I-Nhe I fragment was isolated from the pGEM-T Easy clone and ligated into pGL3-Basic vector (Promega) using Rapid DNA Ligation Kit (Roche) to give pGL3(1601). A series of 5'- truncated reporters (pGL3(1454), pGL3(1274), pGL3(1106), pGL3(656), pGL3(280) and pGL3(122) was similarly prepared with the same reverse primer and with the following sense primers, respectively:

- S334.pgl 5': CTATATGGTACCCATGAACTAGACACCTAGAG;
S415.pgl 5': CTATATGGTACCCTACAAGAAGTTTGAGATCA;
S501.pgl 5': CTATATGGTACCCAGCCGTTGCACCCTCCCAATCAC;
1exD pgl 5' CTATATGGTACCGTCTTGGAGCTCCTAGAGG;
S504.pgl 5' CTATATGGTACCCACCAAAGTCCTGACACTTG and
S139.pgl 5' TTGGTACCCACTGAACTTTGGCTAAAGC..

All PCR products were also cloned into pGL3-Basic vector in the opposite orientation to serve as controls.

Example 16:

Transient transfection assays.

HepG2 or WISH cells in 6 well plates (0.5×10^6 /well) were transfected using FuGENE 6 and the indicated luciferase reporter vector (0.5 μ g/well) and pSV40 β GAL (0.2 μ g/well, Promega) according to manufacturer's instructions. In some cases co-transfection was done with the following expression vectors: pcDNA3-IRF-1 (0.07 – 1.5 μ g/well, kindly provided by Dr. B. Levy, Technion, Israel); pcDNA3-C/EBP β (0.5 – 2.5 μ g/-well, kindly provided by Dr. D. Zipori, Weizmann Institute of Science). After 16 h cells were treated with either IFN γ (100 U/ml), IL-6 (150 U/ml), TNF α (10 ng/ml) or their indicated combinations in serum-free medium for 24 h. Cells were then collected, lysed and Luciferase activity was measured. All results were normalized against β -galactosidase activity.

Example 17:

Preparation of nuclear and cytoplasmic extracts.

Cells were washed 3x with ice-cold phosphate buffered saline (PBS) and immediately frozen in liquid nitrogen. Cell pellets were re-suspended in four packed cell volume of cytoplasmic buffer (10 mM Hepes, pH 7.9, 10 mM NaCl, 0.1 mM EDTA, 5% (by vol.) glycerol, 1.5 mM MgCl₂, 1 mM dithiothreitol (DTT), 0.5 mM PMSF, 50 mM NaF, 0.1 mM Na₃VO₄, 2 mM EGTA, 10 mM EDTA, , 10 mM Na₂MoO₄, 2 μ g/ml each of leupeptin, pepstatin and aprotinin). The lysate was centrifuged (3000xg, 10 min.) and the supernatant containing the cytoplasmic proteins was collected. The pellet was re-suspended in 2.5 packed cell volumes of nuclear buffer (identical to cytoplasmic buffer except that NaCl was increased to 0.42 M). Nuclear debris was removed by centrifugation (15,000xg, 20 min. 4°C), aliquots of the supernatant were frozen in liquid nitrogen and stored at -80°C. Protein concentration was determined by a BCA Protein assay reagent kit (Pierce, Rockford USA) using bovine serum albumin as a standard.

Example 18:

Electrophoretic mobility Shift Assays.

Ds oligonucleotides corresponding to selected response elements (10 pmol) were labeled with [32 P]3 ATP by polynucleotide kinase (New England Biolabs). Nuclear extracts (5 μ g protein) were pre-incubated (15 min., 0°C) together with poly(dI-dC) (Amersham Pharmacia biotechnology) in 20 μ l EMSA Buffer (20 mM Hepes pH 7.5; 5 mM MgCl₂, 2 mM EDTA, 5 mM DTT and 5% (by vol.) glycerol). A labeled probe (3x10⁴ cpm) was then added and incubation continued for an additional 30 min. at room temperature. For super-shift assays samples were incubated with the indicated antibodies (4 μ g, 1 h at 0°C) prior to addition of the probe. A 200 fold excess of wild type and mutated competitors were added together with the relevant probe. Reaction mixtures were then electrophoresed in 5% non-denaturing polyacrylamide gels. Gels were vacuum dried and autoradiographed overnight at -80°C..

Example 19:

Immunoprecipitation (ip) and immunoblot (ib) analysis.

Nuclear or cytoplasmic protein extracts (80 μ g) were incubated with 6 μ g of the indicated polyclonal antibodies overnight at 4°C. and immunoprecipitated with Protein G Sepharose beads (Pharmacia) for 1 h at room temperature. The beads were then boiled in SDS-PAGE sample buffer containing 10% DTT and the supernatant resolved by SDS-PAGE (10% acrylamide) under reducing conditions. The gel was then blotted onto a nitrocellulose membrane and proteins detected with the indicated antibodies. Immune complexes were identified by Super SignalTM (Pierce) detection kit.

Example 20:

Preparation of CHO r-hsLDLR using the IL-18BP promoter.

Stable recombinant CHO cells expressing human soluble LDLR are generated by co-transfection of CHO-DUKX cells lacking the dihydrofolate reductase (DHFR) gene (Urlaub, G. et al., 1980) with two expression vectors: one containing the N-terminal ligand-binding domain of the LDLR, beginning at amino acid residue Asp (+ 4) up to Glu 291 (+291), and pDHFR, containing the murine gene for DHFR, DHFR controlled by the early SV40 promoter and sLDLR gene by the IL-18BP promoter (SEQ ID NO:2) and transcription termination elements of the SV40 early region. Transfection is performed by cationic liposomes using LipofectAmine (Gibco BRL), according to the protocol described by the manufacturer. Seventy-two hours after transfection cells are transferred to a selective medium lacking deoxy and ribonucleosides and supplemented with 10% dialysed FCS. Cells expressing DHFR activity are able to form colonies, which are isolated by lifting the cells with trypsin-soaked paper discs. The cells are grown and screened for r-hsLDLR activity. The transfected cells are then subjected to gene amplification by MTX, followed by subcloning and selection of the stable producer clones.

20

25

REFERENCES

- 5 Bahner 1993 J Virol 67:3199.
Breni et al. 1992 Blood 80:1418.
Boshart et al. 1985 Cell 41 :521.

Brinster et al. (1981) Cell 27 : 233.
Cassel 1993 Exp Hematol. 21 : 585.
- 10 Chao 1993 Blood 81 :2031.
Chen 1997 Nat Med 3:1110
Costantini et al. (1981) Nature 294: 982
Couture 1996 Trends Genet 12: 510.
Dignam et al. 1983 Nucleic Acid Res. 11: 1475
- 15 Dijkema et al. 1985 EMBO J 4 :761.

Dunbar 1995Blood 85 : 3048.

Dylan and Tjian 1985 Nature 316:774.
Dylan W 1989 Cell 58:1-4.
Fletcher et al. 1987 Cell 51 :773-781.
- 20 Fried et al. 1981 Nucleic Acids Res. 9, 6505
Gale et al. 1992 Transplant 9 :151.
Gordon et al. (1976) PNAS 73 : 1260.
Gorman et al 1982b PNAS 79 :6777

Henon et al. 1992 Transplant 9: 285.
- 25 Herzog, R. W., Hagstrom, J. N., Kung, S. H., Tai, S. J., Wilson, J. M., Fisher, K. J. & High, K. A. (1997) *Proc. Natl. Acad. Sci. USA* 94, 5804-5809
Harpers et al. (1981) Nature 293:540.
Hao et al. 1995 Blood 86 :3745.
Junker 1997 Blood 89:4299.
- 30 Kearns 1997 Human Gene Ther 8: 310.
Kohn et al. (1999) Blood 94 :368.
Lee 1994 J. Virol 68:8254

Lili Wang[°], Kazuaki Takabe[†], Scott M. Bidlingmaier[‡], Charles R. III[‡], and Inder M. Verma^{*}
 Vol. 96, Issue 7, 3906-3910, March 30, 1999 Sustained correction of bleeding disorder in hemophilia B mice by gene therapy

Lotti et al. 2002 J of Virol. 76:3996.

5 Malim 1989 Cell 58:205.

Maniatis et al 1987 Science 236 : 1237.

Marasco 1997 Gene Ther 4:11.

Muhl, H., Kampfer, H., Bosmann, M., Frank, S., Radeke, H. & Pfeilschifter, J. (2000) *Biochem. Biophys. Res. Commun.* 267, 960-963.

10 Murphy, J. E., Zhou, S., Giese, K., Williams, L. T., Escobedo, J. A. & Dwarki, V. J. (1997) *Proc. Natl. Acad. Sci. USA* 94, 13921-13926

Neighbors, M., Xu, X., Barrat, F. J., Ruuls, S. R., Churakova, T., Debets, R., Bazan, J. F., Kastelein, R. A., Abrams, J. S. & O'Garra, A. (2001) *J. Exp. Med.* 194, 343-354.

15 Novick, D., Schwartzburd, B., Pinkus, R., Suissa, D., Belzer, I., Sthoeger, Z., Keane, W. F., Chvatchko, Y., Kim, S. H., Fantuzzi, G., Dinarello, C. A. & Rubinstein, M. (2001) *Cytokine* 14, 334-342.

Novick D, Kim SH, Fantuzzi G, Reznikov LL, Dinarello CA, Rubinstein M.

20 Immunity 1999 Jan;10(1):127-36

Novick D, Schwartzburd B, Pinkus R, Suissa D, Belzer I, Sthoeger Z, Keane WF, Chvatchko Y, Kim SH, Fantuzzi G, Dinarello CA, Rubinstein M. *Cytokine* 2001 Jun 21;14(6):334-42

25 McKnight and Tjian 1986 Cell 46:795.

Mioshi et al. 1999 Science 283 : 682.

Moritz 1993 J Exp Med 178:529.

Palmiter et al. 1986 Ann Rev. Genet. 20:465.

Revzin 1989 Biotechniques 7:346

30 Sassone-Corsi and Borreli 1986 Trends Genet 2:215

Scheidereit et al. 1987 Cell 51 : 783-793.

Slobod 1996 Blood 88, 3329

Snyder, R. O., Miao, C. H., Patijn, G. A., Spratt, S. K., Danos, O., Nagy, D., Gown, A. M., Winther, B., Meuse, L., Cohen, L. K., et al. (1997) *Nat. Genet.* 16, 270-276

Snyder, R. O., Miao, C., Meuse, L., Tubb, J., Donahue, B. A., Lin, H. F., Stafford, D. W., Patel, S., Thompson, A. R., Nichols, T., *et al.* (1999) *Nat. Med.* 5, 64-70

Song, S., Morgan, M., Ellis, T., Poirier, A., Chesnut, K., Wang, J., Brantly, M., Muzyczka, N., Byrne, B. J., Atkinson, M., *et al.* (1998) *Proc. Natl. Acad. Sci. USA* 95, 14384-14388

5 Sullenger 1990 *Cell* 63:601.

Veres et al. 1996 *J Virol* 70 : 8792

Verma et al. 1997 *Nature* 389 :239.

Voss et al. 1986 *Trends Biochem Sci.* 11 :287.

Wagner et al. (1981) *PNAS* 78:5016

10 Xiao, W., Berta, S. C., Lu, M. M., Moscioni, A. D., Tazelaar, J. & Wilson, J. M. (1998) *J. Virol.* 72, 10222-10226

Zecchina G, Novick D, Rubinstein M, Barak V, Dinarello C, Nagler A. *J Hematother Stem Cell Res.* 2001 Dec;10(6):769-76.

Zhou 1994 *Gene* 149:33.

15 Zweibel et al. 1989 *Science* 243 : 220.

CLAIMS:

- 5 1. A DNA sequence comprising SEQ ID NO:1 encoding the human IL-18BP promoter, or a fragment or a functional derivative thereof.
2. A DNA sequence according to claim 1, comprising the sequence in SEQ ID NO:2 .
- 10 3. A DNA sequence according to claim 2, comprising the sequence in SEQ ID NO:3.
4. A DNA sequence according to anyone of claims 1 to 3, further comprising an intron.
5. A DNA sequence according to claim 4, wherein the intron consists of the first intron of IL-18BP.
- 15 6. A DNA sequence according to anyone of the previous claims, further containing a gene operatively linked to the IL-18BP promoter.
7. A DNA sequence according to claim 6 wherein the gene encodes IL-18BP.
8. A DNA sequence according to claim 6 wherein the gene encodes a heterologous protein.
- 20 9. A DNA sequence according to claim 8, wherein the heterologous gene encodes the luciferase gene.
10. A DNA sequence according to claim 8, wherein the heterologous gene encodes a protein selected from interferon-beta, TNF, erythropoietin, tissue plasminogen activator, granulocyte colony stimulating factor, manganese-superoxide
25 dismutase, an immunoglobulin, or fragment thereof, growth hormone, FSH, hCG, IL-18, hsLDLR and TNF receptor binding proteins.

11. A vector comprising the DNA sequence of SEQ ID NO:1.
12. A vector according to claim 11, comprising a DNA sequence of SEQ ID NO:2.
13. A vector according to claim 12, comprising a DNA sequence of SEQ ID NO: 3.
14. A vector according to anyone of claims 11 to 13, further comprising an intron.
- 5 15. A vector according to claim 14, wherein the intron consist of the first intron of IL-18BP.
16. A vector according to anyone of claims 11 to 15, further containing a gene operably linked to the IL-18BP promoter.
17. A vector according to claim 16, wherein the gene is heterologous.
- 10 18. A vector according to claim 17, wherein the heterologous gene encodes luciferase.
19. A vector according to claim 17, wherein the heterologous gene encodes a protein selected from interferon-beta, TNF, erythropoietin, tissue plasminogen activator, granulocyte colony stimulating factor, manganese-superoxide dismutase, an immunoglobulin, or fragment thereof, growth hormone, FSH, hCG, IL-18, TNF receptor binding proteins, hsLDLR and IL-18 binding proteins.
- 15 20. A host cell comprising an expression vector according to anyone of claims 11 to 19.
21. A host cell according to claim 15, being a mammalian cell.
- 20 22. A host cell according to claim 21, selected from CHO, WISH, HepG2, Cos, CV-1, HeLA, and Hakat U937 cells.
23. A method for the production of a recombinant protein comprising culturing a host cell according to anyone of claims 20 to 22 and isolating the recombinant protein produced.
- 25 24. A method according to claim 23 wherein the protein is selected from interferon-beta, TNF, erythropoietin, tissue plasminogen activator, granulocyte colony stimulating factor, manganese-superoxide dismutase, an immunoglobulin, or

fragment thereof, growth hormone, FSH, hCG, IL-18, TNF receptor binding proteins, hsLDLR and IL-18 binding proteins.


- 5 25. A recombinant virus vector which comprises a portion of the virus genome and a DNA fragment encoding a gene of interest and a DNA fragment comprising SEQ ID NO:1 or a fragment thereof, or a functional derivatives thereof encoding the human IL-18BP promoter, operably linked to the gene of interest.
26. A recombinant virus vector according to claim 25, wherein the promoter comprises SEQ ID NO:1.
- 10 27. A recombinant virus vector according to claim 25, wherein the promoter comprises SEQ ID NO:2.
28. A recombinant virus vector according to claim 25, wherein the promoter comprises SEQ ID NO: 3.
29. A recombinant virus vector according to anyone of claims 25 to 28, further comprising an intron.
- 15 30. A recombinant virus vector according to claim 29, wherein the intron consist of the first intron of IL-18BP.
31. A recombinant virus vector according to anyone of claims 25 to 30, wherein the portion of the virus genome belongs to an adeno associated virus.
32. A recombinant virus vector according to anyone of claims 25 to 30, wherein the portion of the virus genome belongs to a retrovirus.
- 20 33. A recombinant virus vector according to claim 32, wherein the retrovirus is selected from HIV, HFV, MLV, FIV and VSV.
34. A method of regulating cell specific expression of a gene of interest, for the treatment of a disease, comprising stably transducing a target mammalian immune cell with a vector according to anyone of claims 25 to 33 and transplanting such cell in an individual in need.
- 25 35. A method according to claim 34, wherein the target cell is an hematopoietic stem cell.

36. A method according to claim 34, wherein the target cell is a monocyte.
37. A method according to claim 34, wherein the target cell is a macrophage.
38. A method according to anyone of claims 34 to 37, wherein the gene of interest encodes a protein conferring resistance to HIV infection.
- 5 39. A method according to claim 38, for the treatment of HIV infection.
40. A method according to anyone of claims 34 to 37 for the treatment of hematopoietic disorders.
41. A method according to claim 40, wherein the hematopoietic disorder is selected from SCID, chronic granulomatous disease and thalassemia.
- 10 42. A method of gene therapy for the treatment of a disease in an individual exhibiting elevated IFN γ in a body tissue, comprising the administration of an effective amount of a vector according to anyone of claims 25 to 33.
43. A method according to claim 42 further comprising the administration of IL-6 and/or TNF- α and or IRF and or C/EBP β factors.
- 15 44. Transgenic mice harbouring the human IL-18BP promoter.

For the applicant



Henry Einav

**Figure 1**




Figure 2





Figure 3

**Figure 4**





Figure 5

**Figure 6**




Figure 7




Figure 8

596.ST25
SEQUENCE LISTING

<110> Yeda Research and Development Co. Ltd
Rubinstein, Menachem
Novick, Daniela
Hurgin, Vladimir

<120> PROMOTOR TO IL-18BP, ITS PREPARATION AND USE

<130> 596

<160> 4

<170> PatentIn version 3.1

<210> 1

<211> 1272

<212> DNA

<213> Homo sapiens

<400> 1
catgaactag acacctagag aagaaggatg tgacttgtag taccctatgt ctaaattagg 60
aatatgaatc tggtttttct acaagaagtt tgagatcaca gctgactgtg ttcctgatgc 120
atccaccaa cccagttcca tctgtgggccc tccctggctc tgtcaccagc cgttgcaccc 180
tcccaatcac aggagtcaca aacctcagac atgcagctcc tgtccacact taatatatgc 240
atgcattgga tcaccagacc ctggtccttc tgcctccatg gataactgca tgaccctgag 300
agaaaacctc cttagattta gcatcctagg ttcctcacac gcctcaccct gaatcctggc 360
cctcccgcag cccagcgcc atttgtcca tcagtgacaa gattcatatt ctgatgtaga 420
ctctgttgcc agagccagtg ttgagccagt ccgcctcttc cccgggaagt gcctgccctt 480
ccctcctggt aggggttggt ctcgagcttg tgtgccagtt cctggggttg ccgtgagagt 540
tctacagaca aggaggaagt gctctcggtg tatttcctgt ggtgggttca cacgcagcta 600
gacacagcta acttgagtct tggagctcct agagggaagc ttctggaaag gaaggctctt 660
caggacctct taggagccag gtaggagtct gggactacta gtgaacctag acctgtggct 720
ctggccagag gggctaggat gagagacaga ggggtgtgatg gtgggtgctg ggagatgtag 780
ccgaccttgg ggctggtggc tgggggagtg ggtagcctgg gaaaggccag gatgtggacg 840

596.ST25

gactggtatg gcattgagcc tgaagtggc caacttgggg ttccccagtg cctaggaaag	900
ttgtccccctt gaatgtcagt gtgaagggtga aggaggaagc agatgcctgt tcatatggaa	960
acaaagacct ggctgtgaag aggggaggcg gacaccaaag tcctgacact tgggcgggac	1020
agaattgatc tgtgagagac tcatctagtt cataccctag gtgaccctgg ggggtggcatg	1080
ggggttagatt agagatccca gtctgggtatc ctctggagag taggagtccc aggagctgaa	1140
ggtttctggc cactgaactt tggctaaagc agaggtgtca cagctgctca agattccctg	1200
gttaaaaagt gaaagtgaaa tagagggtcg gggcagtgct ttcccagaag gattgctcgg	1260
catcctgccc tt	1272

<210> 2

<211> 634

<212> DNA

<213> Homo sapiens

<400> 2	
gcttctggaa aggaaggctc ttcaggacct cttaggagcc aggtaggagt ctgggactac	60
tagtgaacct agacctgtgg ctctggccag aggggctagg atgagagaca gaggggtgtga	120
tgggtgggtgc tgggagatgt agccgacctt ggggctgggtg gctgggggag tgggtagcct	180
gggaaaggcc aggatgtgga cggactggta tggcattgag cctgaagtgg tccaacttgg	240
ggttccccag tgcctaggaa agttgtcccc ttgaatgtca gtgtgaaggt gaaggaggaa	300
gcagatgcct gttcatatgg aaacaaagac ctggctgtga agaggggagg cggacaccaa	360
agtcctgaca cttgggcggg acagaattga tctgtgagag actcatctag ttcataacct	420
aggtgacctt ggggggtggca tgggggtaga ttagagatcc cagtctggta tcctctggag	480
agtaggagtc ccaggagctg aagggttctg gccactgaac tttggctaaa gcagagggtgt	540
cacagctgct caagattccc tgggttaaaaa gtgaaagtga aatagagggt cggggcagtg	600
ctttcccaga aggattgctc ggcacacctg cctt	634

<210> 3

<211> 122

<212> DNA

<213> Homo sapiens

<400> 3	
cactgaactt tggctaaagc agaggtgtca cagctgctca agattccctg gttaaaaagt	60
gaaagtgaaa tagagggtcg gggcagtgct ttcccagaag gattgctcgg catcctgccc	120
tt	122

596.ST25

<210> 4

<211> 1061

<212> DNA

<213> Homo sapiens

<400> 4

tgcagctcct gtccacactt aatatatgca tgcattggat caccagccc tggctcttct	60
gcctccatgg ataactgcat gaccctgaga gaaaacctcc ttagatttag catcctaggt	120
tcctcacacg cctcacctg aatcctggcc ctcccgcagc cccagcgcca ttgtcccat	180
cagtgacaag attcatattc tgatgtagac tctgttgcca gagccagtgt tgagccagtc	240
cgcctcttcc ccgggaagtg cctgcccttc ctcctgttta gggttggctc tcgagcttgt	300
gtgccagttc ctgggttggc cgtgagagtt ctacagacaa ggaggaagtg ctctcggtgt	360
atttcctgtg gtgggttcac acgcagctag acacagctaa cttgagtctt ggagctccta	420
gaggaagct tctggaaagg aaggctcttc aggacctctt aggagccagg taggagtctg	480
ggactactag tgaacctaga cctgtggctc tggccagagg ggctaggatg agagacagag	540
ggtgtgatgg tgggtgctgg gagatgtagc cgaccttggg gctggtggct gggggagtgg	600
gtagcctggg aaaggccagg atgtggacgg actggtatgg cattgagcct gaagtgggtcc	660
aacttggggg tccccagtgc ctaggaaagt tgtccccttg aatgtcagt tgaaggtgaa	720
ggaggaagca gatgcctgtt catatggaaa caaagacctg gctgtgaaga ggggaggcgg	780
acaccaaagt cctgacactt gggcgggaca gaattgatct gtgagagact catctagttc	840
ataccctagg tgaccctggg ggtggcatgg gggtagatta gagatcccag tctggtatcc	900
tctggagagt aggagtcca ggagctgaag gtttctggcc actgaacttt ggctaaagca	960
gaggtgtcac agctgctcaa gattccctgg ttaaaaagtg aaagtgaaat agaggggtcgg	1020
ggcagtgcct tcccagaagg attgctcggc atcctgcct t	1061

This Page is inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☒ BLURED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLORED OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REPERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images
problems checked, please do not report the
problems to the IFW Image Problem Mailbox**